Lonza to Invest in Portsmouth, NH (USA) Site, Including Mid-Scale Biologics
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: 2 minutes
Lonza Pharma & Biotech
announced the
investment
in
a new phase of development at their Portsmouth
, NH
(USA)
site.
The
expansion will include mid-scale
mammalian
capacity
and
the addition of new cell-therapy
suites.
With this
latest
round of growth, Lonza
Portsmouth
confirms its position
as a
leading
-
house
in
biologics
manufacturing
and
ensures
capacity for customers in the
years ahead.
Lonza is installing multiple 6,000L bioreactors at the site to
meet
existing and new
customers' needs
,
with building
expected to
start in
late
2018.
Further expansion of mid-scale capacity
is seen as a key
area
of growth
by
the Swiss-based manufacturer
, driven by several factors including a
favorable regulatory environment for developing products
for
niche indications
. Lonza’s Portsmouth site
is ideally
placed
for the
addition of mid
-
scale capacity within
their
existing global network, which ranges from
small
,
single
-
use
bioreactors
to
large
-
scale
assets.
The new facilities have been designed to ensure
reliable
delivery of innovative medicines.
With
a
strong
focus on
automation
,
Lonza
is implementing
full-suite process
analytic technology (
PAT) and advanced multi-variate
analysis (MVA) to ensure consistent performance.
The
hybrid facility
,
which also incorporates state-of-the-art
,
single-use technologies for simplified processing,
will be
installed in
an
existing building.
“
These new facilities have been designed specifically
to
deliver for
our
customers
and their patient
s
,” commented
Marc Funk, COO
Lonza Pharma & Biotech
. “They will be
enabled by cutting-edge technology
developed with
our
R&D team and the decades of expertise at our Portsmouth
site”
In addition, Lonza is
installing
multiple cell-therapy suites at
the Portsmouth site. In
February
2018, the company
established centers of excellence in cell and gene
therapy
across its network
,
placing
Portsmouth
as
a
clinical and
commercial manufacturing center in this emerging
technology.
Customers will have access to facilities for
phase I through to commercial
manufacturing
under one
roof,
expected to be fully operational
by late 2018
.
announced the
investment
in
a new phase of development at their Portsmouth
, NH
(USA)
site.
The
expansion will include mid-scale
mammalian
capacity
and
the addition of new cell-therapy
suites.
With this
latest
round of growth, Lonza
Portsmouth
confirms its position
as a
leading
-
house
in
biologics
manufacturing
and
ensures
capacity for customers in the
years ahead.
Lonza is installing multiple 6,000L bioreactors at the site to
meet
existing and new
customers' needs
,
with building
expected to
start in
late
2018.
Further expansion of mid-scale capacity
is seen as a key
area
of growth
by
the Swiss-based manufacturer
, driven by several factors including a
favorable regulatory environment for developing products
for
niche indications
. Lonza’s Portsmouth site
is ideally
placed
for the
addition of mid
-
scale capacity within
their
existing global network, which ranges from
small
,
single
-
use
bioreactors
to
large
-
scale
assets.
The new facilities have been designed to ensure
reliable
delivery of innovative medicines.
With
a
strong
focus on
automation
,
Lonza
is implementing
full-suite process
analytic technology (
PAT) and advanced multi-variate
analysis (MVA) to ensure consistent performance.
The
hybrid facility
,
which also incorporates state-of-the-art
,
single-use technologies for simplified processing,
will be
installed in
an
existing building.
“
These new facilities have been designed specifically
to
deliver for
our
customers
and their patient
s
,” commented
Marc Funk, COO
Lonza Pharma & Biotech
. “They will be
enabled by cutting-edge technology
developed with
our
R&D team and the decades of expertise at our Portsmouth
site”
In addition, Lonza is
installing
multiple cell-therapy suites at
the Portsmouth site. In
February
2018, the company
established centers of excellence in cell and gene
therapy
across its network
,
placing
Portsmouth
as
a
clinical and
commercial manufacturing center in this emerging
technology.
Customers will have access to facilities for
phase I through to commercial
manufacturing
under one
roof,
expected to be fully operational
by late 2018
.
